Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Scholar Rock Holding (SRRK – Research Report), Twist...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, Uy Ear from Mizuho Securities upgraded Sarepta Therapeutics to a Buy, with a price target of $26.00. The company’s shar...

Mizuho Securities upgrades Sarepta Therapeutics (SRPT) to a Buy

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avadel Pharmaceuticals (AVDL – Research Report) and Sarepta Thera...

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Sarepta Therapeutics (SRPT)

RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics yesterday and set a price target of $16.00. The company’s share...

RBC Capital Remains a Hold on Sarepta Therapeutics (SRPT)

H.C. Wainwright analyst Mitchell Kapoor reiterated a Sell rating on Sarepta Therapeutics today and set a price target of $5.00. The company’s share...

Sarepta Therapeutics (SRPT) Gets a Sell from H.C. Wainwright

Shares of Sarepta Therapeutics ($SRPT) plunged after the company reported disappointing results from a key trial of its Duchenne muscular dystrophy...

Why Is Sarepta Stock (SRPT) Crashing in Pre-Market Today?

Sarepta Therapeutics Inc. ( ($SRPT) ) has released its Q3 earnings. Here is a breakdown of the information Sarepta Therapeutics Inc. presented to i...

Sarepta Therapeutics Reports Q3 2025 Financial Results

Sarepta Therapeutics Inc. (($SRPT)) announced an update on their ongoing clinical study. Study Overview: The study titled ‘A Two-Part, Open-Label S...

Current Quarter	$-0.85	Next Quarter	$0.32
Current Year	$-3.4	Next Year	$1.82
QoQ Growth	+137.6%	YoY Growth	+153.5%
3Y EPS CAGR	+35.4%	Target Price	$20.73
Consensus	Buy	Upside	+17.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRPT	$17.69	+7.34%	3.94M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SRPT	$17.69	+7.3%	3.94M
3
4
5
6

SRPT

SRPT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Sarepta Therapeutics Inc. Data in Excel

Get Sarepta Therapeutics Inc. Data in Excel